$0.56
-0.05 (-7.59%)
Open$0.60
Previous Close$0.61
Day High$0.60
Day Low$0.55
52W High$2.10
52W Low$0.54
Volume—
Avg Volume321.5K
Market Cap52.14M
P/E Ratio—
EPS$-1.59
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+8,283.9% upside
Current
$0.56
$0.56
Target
$46.95
$46.95
$33.28
$46.95 avg
$64.49
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 47.89M | 42.94M | 46.10M |
| Net Income | 949.8K | 770.7K | 699.4K |
| Profit Margin | 2.0% | 1.8% | 1.5% |
| EBITDA | 1.44M | 1.43M | 1.37M |
| Free Cash Flow | 717.1K | 500.4K | 604.2K |
| Rev Growth | -0.9% | +8.9% | +4.5% |
| Debt/Equity | 0.33 | 0.39 | 0.43 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |